Massard, C., Mateo, J., Loriot, Y., Pezaro, C., Albiges, L., Mehra, N., . . . de Bono, J. (2017). Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone. Ann Oncol.
Chicago-tyylinen lähdeviittausMassard, C., et al. "Phase I/II Trial of Cabazitaxel Plus Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Progressing After Docetaxel and Abiraterone." Ann Oncol 2017.
MLA-viiteMassard, C., et al. "Phase I/II Trial of Cabazitaxel Plus Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Progressing After Docetaxel and Abiraterone." Ann Oncol 2017.
Varoitus: Nämä viitteet eivät aina ole täysin luotettavia.